Neuromyelitis optica spectrum disorder Interventions

Neuromyelitis optica spectrum disorder Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuromyelitis optica spectrum disorder from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Interventions
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuromyelitis optica spectrum disorder Interventions On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder Interventions All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuromyelitis optica spectrum disorder Interventions
CDC on Neuromyelitis optica spectrum disorder Interventions
Neuromyelitis optica spectrum disorder Interventions in the news
Blogs on Neuromyelitis optica spectrum disorder Interventions
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder Interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes

Overview

Interventions in neuromyelitis optica spectrum disorder (NMOSD) primarily involve therapeutic apheresis to treat acute inflammatory attacks. Prompt treatment and early escalation help limit permanent neurological disability.

The 2026 American Society for Apheresis (ASFA) guidelines classify therapeutic plasma exchange (TPE) and immunoadsorption (IA) for acute NMOSD attacks as Category I interventions, recognizing their use as first-line treatment alongside high-dose corticosteroids.

For corticosteroid regimens and preventive immunotherapy, see medical therapy.

Interventions

Therapeutic Plasma Exchange

Neuromyelitis optica spectrum disorder attacks may be treated with TPE, which removes circulating antibodies and other plasma proteins. Separated plasma is discarded, and blood cells are returned with replacement fluid.

• Volume exchanged: Usually 1–1.5 estimated total plasma volumes per session.
• Frequency: Daily or every other day, commonly with approximately five treatments initially. The course is adjusted to clinical response.
• Replacement fluid: Albumin or plasma, selected according to the patient's clinical circumstances and the apheresis protocol.
• Additional sessions: Up to ten treatments may be considered in selected patients with an inadequate response.

Immunoadsorption

Neuromyelitis optica spectrum disorder attacks may also be treated with IA. Separated plasma passes through an adsorber that removes immunoglobulins before the treated plasma is returned; routine replacement of the entire plasma volume is unnecessary.

The processed volume and treatment schedule depend on the adsorber system and local protocol. The Neuromyelitis Optica Study Group (NEMOS) accepts either TPE or IA, while noting greater clinical experience with TPE.

A retrospective study of 207 attacks in 105 patients did not establish superiority of either procedure. This observational evidence does not prove equivalence.

Indications and Timing

Neuromyelitis optica spectrum disorder attacks require urgent assessment for apheresis when neurological deficits are severe or recovery after corticosteroids is insufficient.

• Inadequate corticosteroid response: Begin apheresis early when improvement is insufficient during the first few days of high-dose corticosteroid treatment.
• Severe attacks: Early combined corticosteroid and apheresis treatment may be appropriate. Severe myelitis is a recognized indication for considering apheresis as initial treatment.
• Previous treatment response: Consider early apheresis when previous attacks responded poorly to corticosteroids or well to apheresis.

Earlier treatment was associated with a greater likelihood of complete recovery in observational studies. Apheresis should not be unnecessarily delayed while waiting for a prolonged corticosteroid trial.

Pretreatment Assessment and Monitoring

Neuromyelitis optica spectrum disorder patients undergoing apheresis require assessment and monitoring according to general therapeutic apheresis recommendations.

• Assess vascular access, fluid balance, and medication use.
• Obtain a complete blood count, calcium, potassium, and coagulation parameters before the first treatment.
• Monitor blood pressure, heart rate, and oxygen saturation during treatment.
• Monitor for citrate-related hypocalcemia and provide calcium supplementation when indicated.

Adverse Effects and Precautions

Neuromyelitis optica spectrum disorder patients should be monitored for hypotension, citrate-related symptoms such as perioral tingling, allergic reactions, fluid imbalance, coagulation disturbances, and vascular-access complications. Bleeding risk and hemodynamic status require individual assessment.

Coordination with Complement Inhibitors

Neuromyelitis optica spectrum disorder patients receiving eculizumab or ravulizumab need coordinated treatment planning when TPE is performed. Plasma exchange reduces drug concentrations, and supplemental dosing is required according to the applicable prescribing information.

Response and Further Management

Neuromyelitis optica spectrum disorder with incomplete recovery after an initial treatment course warrants specialist reassessment. Additional apheresis or corticosteroid treatment may be considered when significant deficits persist.

Attack recovery should be followed by an individualized plan for long-term relapse prevention. See medical therapy for preventive immunotherapy.

Maintenance Apheresis

Neuromyelitis optica spectrum disorder maintenance TPE has been used in selected refractory cases. ASFA assigns maintenance TPE to Category III, meaning that its optimal role is not established and decisions should be individualized. Evidence for maintenance IA is limited to small observational reports.